| Typicality: | 0.313 |
| Saliency: | 0.338 |
| in certain cancers | 6 | location |
| in crohn’s disease | 3 | location |
| to naltrexone | 2 | other |
| drug → stop → the progression of the disease | 11 |
| drug → stop → disease progression | 6 |
| drug → halt → the progression of the disease | 5 |
| drug → prevent → disease progression | 4 |
| drug → be shown to halt → disease progression | 3 |
| drug → prevent → the progression of the disease | 3 |
| drug → control → disease progression | 3 |
| drug → halt → progression of the disease | 3 |
| negative | neutral | positive |
| 0.213 | 0.540 | 0.247 |
| Raw frequency | 38 |
| Normalized frequency | 0.338 |
| Modifier score | 0.250 |
| Perplexity | 22.499 |